Screening Market- Industry Trends & Forecast Report 2027
The global blood screening market was worth USD 1.8 billion in 2020 and is further
projected to reach USD 4.0 billion by 2027, at a CAGR of 11.1% during the
forecast period (2021-2027). This sharp rise can be attributed to the
increasing awareness about blood donations, increased frequency in the
occurrence of various infectious diseases, as well as programs undertaken by
government and non-government organizations. Blood screening methods are used
to identify various infectious diseases such as HBV (hepatitis B), HCV
(hepatitis C), HIV1 (Human immunodeficiency virus), COVID-19, HIV2, and others
in donated blood in order to ensure the safety of the process of blood
Blue Weave Consulting
Blood Screening Market Overview
ensure healthy blood units, essential procedures must be followed during the
examination of donated blood and the separation of blood and blood components. Depending
on the outcome of the tests, they are either issued for therapeutic use or
manufacturing, or they are disposed of. Different procedures, reagents, kits,
instruments, and software are used to conduct laboratory tests on blood samples
obtained during donation. All blood sample tests are performed and recorded in
well-equipped laboratories using tried-and-true procedures. All blood samples,
donations, and components are marked with the appropriate label to ensure
proper identification throughout the testing process. Strong guidelines are in
place to avoid errors that lead to dangerous blood transfusions.
Blood Screening Market Trend
Awareness for Blood Donations
and pre-transfusion research have become more common as a result of efforts by
numerous organizations and governments. According to the WHO, approximately 108
million blood donations are collected annually worldwide. Half of these blood
donations are received in poor countries with less than 20% of the population. Rising
recognition and high demand for safe blood necessitate the development of
suitable testing technologies, reagents, kits, and other items to build
opportunities for developing countries. Furthermore, the rate of testing for
hepatitis B, hepatitis C, and viruses has nearly doubled in many countries,
generating an ever-increasing demand for blood testing kits for different
diseases, which is creating opportunities in the global blood screening
industry. To encourage volunteers, the WHO had also set a goal to provide safe
access to blood worldwide. Similarly, the Australian Red Cross launched a
project called "First Blood: Overcoming Donor Fear," which encourages
people to donate blood by providing a toolkit to help first-time donors
overcome their anxiety. These programs raise voluntary investments and are
expected to shift the demand over the forecast period.
Frequency of Newer Pathogens
recent years, there has been an unexpected increase in the number of novel
infections caused by bacteria, viruses, fungi, zoonotic diseases (diseases
transmitted by animals), and so on. Additionally, various pathogens also attack
the living organisms through various vectors (virus in most cases). In
addition, comprehensive R&D is being promoted continually to classify
the characteristics of pathogens for diagnosing their presence in the
blood. A physician will usually recommend a blood test to patients in order to
detect any serious diseases or complications in advance. To prioritize R&D
in public health emergency contexts, recently, the WHO is constantly focusing
on the high risk of various potential pathogens and diseases like COVID-19,
Crimean-Congo hemorrhagic fever, Ebola virus disease, and Marburg virus
disease, Lassa fever, Middle East respiratory syndrome coronavirus (MERS-CoV),
and Severe Acute Respiratory Syndrome (SARS), Nipah and henipaviral diseases,
Rift Valley fever, Zika, and so on.
Cost and Unreliable Results are Expected to Hinder the Market Growth
shortage of trained professionals with less knowledge has been a major
challenge to this market. Moreover, blood tests that involve direct contact
with the body may be inconvenient for patients and pose a significant risk of
infection transmissions, such as Hepatitis A, and B, or HIV. Also, some blood
testing devices are very costly, and they necessitate the use of sensors every
month. Additionally, since certain blood test kits are inaccurate and can
generate an incorrect result, self-testing puts the patient's life at risk. These
are some factors that are impeding the growth of the global blood screening
COVID-19 epidemic has created havoc on the global economy. Due to high levels
of infection and the detrimental effects on public health systems, many
countries have had to tighten national closures, impacting supply chains in
manufacturing, commerce, and other related services in particular. The world is
currently searching for new ways for independent laboratories to extend their
research. However, curfews and lockdown worldwide have almost halted the blood
donations, decreased/canceled collection drives, diminished the demand for
donated blood, and has adversely affected the growth of the blood screening
market during the forecasted period globally. However, since the lockdown
restrictions are being eased by the governments of different countries, the
number of blood donors has increased.
Blood Screening Market: By Product and Services
product and services category broadly consists of reagents and kits, NAT
reagents and kits, ELISA reagents and kits, other reagents and kits,
instruments, outright purchase, rental purchase, and software and services. Among
these, the reagents and kits segment has dominated the market. The large share
of this category is mainly due to the frequent utilization of reagents and
kits, increased transfusion-related screenings, increased blood donations, and
the increasing incidence of chronic or infectious diseases. In addition,
reagents are cost-effective for customers and offer a high return on retail
high cost and reusable nature of the Instruments can hinder the growth of the
blood test market. However, following consumer acceptance for the launch of
instruments, the growing success of the instrument segment cannot be ignored. For
instance, the FDA (Food and Drug Administration) approved Roche’s Cobas Zika
donor screening test for the Zika virus. This can prevent the spread of the
Zika virus in the U.S. through blood donations.
Blood Screening Market: By Technology
on the technology the global blood screening market is fragmented into nucleic
acid testing, enzyme-linked immunosorbent assay, rapid test, western blot
assay, next-generation screening.
nucleic acid amplification test (NAT) is growing at the fastest rate due to its
high sensitivity and specificity for viral nucleic acid. The test can detect
nucleic acid earlier than other screening techniques and thus, shrinks the
window period of HBV (hepatitis B), HCV (hepatitis C), and HIV (human immune
deficiency virus) infections.
Blue Weave Consulting
Blood Screening Market: By End-User
on end-user, the global blood screening market is broadly classified into two
categories--hospitals and blood banks. Both blood banks, as well as hospitals, follow
almost a similar channel to procure blood and then making it available to a
patient in need. People may willingly donate blood, which is usually
accompanied by the issuance of a donor card, which can be used in the future to
obtain any form of blood required by the patient. Following COVID-19, all blood
banks and hospitals are under intense pressure to supply blood for safe
transfusions in COVID patients.
Blood Screening Market: Regional Insights
the global blood screening market is categorized into North
America, Europe, the Asia-Pacific, the Middle East & Africa, And Latin
America. North America accounted for the largest market share, followed by
Europe. Factors such as the evolving demand for donated blood, the increasing
number of blood donations, the high prevalence of infectious diseases, and the
high prevalence of novel pathogens, the presence of high-quality infrastructure
for hospitals and clinical laboratories, and the presence of major market
players in the region are some of the driving factors leading to the growth of
the blood screening market in North America. Furthermore, the Asia Pacific
region is growing at the fastest rate in the global blood screening market,
owing to rising patient affordability, increased awareness about blood
donation, and increased emphasis of major industry players on emerging
countries in the region.
high growth potential of the global blood screening market has drawn several
new entrants, creating a lucrative opportunity. The emergence of new entrants
has also resulted in healthy competition among long-established service
providers in the industry.
market seems to be fragmented having the key players namely Grifols, F. Hoffmann-La
Roche AG, Abbott Laboratories, BioMérieux, Bio-Rad Laboratories, Siemens
Healthineers, Danaher Corporation, Thermo Fisher Scientific Inc., Ortho
Clinical Diagnostics, Inc., Becton, Dickinson and Company, DiaSorin, GFE,
Trinity Biotech, Merck Millipore, GE Healthcare, Perkin Elmer, and Bio-Techne
Abbott Laboratories (U.S.) received EUA (emergency use authorization) from
the FDA for its chemiluminescent microparticle immunoassay (CMIA).
Bio-Rad Laboratories, Inc. (U.S.) received EUA (emergency use
authorization) for its modified ELISA—The Platelia SARS-CoV-2 Total Ab
assay, which measures antibodies.
Historical data – 2017-2020
Base Year – 2020
Forecast – 2021 – 2027
Revenue in USD Billion
Germany, U.K., France, Italy, Spain, Japan, China, India, Australia, Brazil,
Mexico, South Africa, Saudi Arabia, U.A.E.
Products and Services, By Technology , By End-User, and By Region
Becton-Dickson and Company, Bio-Rad Laboratories, Danaher Corporation, F.
Hoffman-La Roche, Ltd., Grifols, Ortho Clinical Diagnostic, Siemens
Helthineers, SOFINA s. a.
(Biomérieux), Thermo Fisher Scientific
Product and Services
Ø Reagents and Kit
NAT Reagents and Kit
§ Enzyme and Polymerases
§ Standards and Controls
§ Probes and Primes
§ Buffers, Nucleotides, and
§ Labeling and Detection Reagents
Ø Elisa Reagents and Kits
§ Sample Diluents and Wash Solutions
Ø Other Reagents and Kits
Ø Outright Purchase
Ø Rental purchase
Ø Software and services
Ø Nucleic Acid Testing
Real-Time Polymerase Chain
Ø Enzyme-Linked Immunosorbent Assay
Ø Rapid Tests
Ø Western Blot Assay
Ø Next-Generation Sequencing
Ø Blood Banks
Ø North America
Rest of Europe
Ø Asia Pacific
Rest of Asia-Pacific
Rest of Latin America
Ø The Middle East and Africa
Rest of MEA
What is the current size of the global blood screening
Answer: The global blood screening market has reached
USD 1.8 billion in 2020.
What are the major factors driving the growth of the
global blood screening market?
Answer: Increased awareness for blood donations, high
prevalence of infectious disease, increased initiatives by the government as
well as non-government bodies are the major factors driving the market growth.
Who are the key players in the global blood screening
Answer: The key players operating in the global blood
screening market are Abbott Laboratories, Becton-Dickson,
and Company, Bio-Rad Laboratories, Danaher Corporation, F. Hoffman-La Roche, Ltd., Grifols, Ortho
Clinical Diagnostic, Siemens Helthineers, SOFINA s. a.
(Biomérieux), Thermo Fisher Scientific.
Which category accounted for the largest share in the
global blood screening market by products and services?
Answer: Reagents and kits accounted for the largest share in
the global blood screening market.
Which region is growing at a higher rate in the global
blood screening market?
The Asia Pacific is the fastest-growing region due to rising patient
affordability, increasing awareness about blood donation, and enhanced focus of
key industry players on emerging countries in the region.